贝伐单抗联合伊立替康治疗结直肠癌中实施个性化叙事护理的作用

Role of Implementing Personalized Narrative Nursing Amdist Treating Colorectal Cancer by Bevacizumab Combined with Irinotecan

为分析结直肠癌患者中应用贝伐单抗、伊立替康治疗联合个性化叙事护理的临床价值,将68例结直肠癌患者随机分为观察组和对照组,每组34例。2组患者均给予贝伐单抗联合伊立替康治疗,对照组患者采用常规护理,观察组患者在常规护理的基础上采用个性化叙事护理,比较2组患者干预后的效果。结果显示,观察组患者的治疗依从率为94.12%,明显高于对照组的73.53%(P <0.05);观察组患者的主观幸福感评分明显高于对照组(P <0.05)。结果表明,贝伐单抗联合伊立替康治疗结直肠癌患者中应用个性化叙事护理,能够提高患者的治疗依从性和主观幸福感,可促进患者的身体康复。

This study was to investigate the clinical value of implementing personalized narrative nursing(PNN)amdist treating colorectal cancer patients into two groups all receiving(bevacizumab plus irinotecan)treatment,in which control group was given routine nursing,while observation group was added with PNN based on routinc nursing;then,compared both groups’ efficacy of nursing intervention.As results,in treatment compliance rate,and in patients’ subjective well-being ratings,observation group was respectively and significantly higher(94.12% vs 73.53%),and higher than control group(all,P <0.05).Resutls show that amdist(bevacizumab plus irinotecan)for treating colorectal cancer implementing PNN can enhance patients’ compliance to treatment,and subjective well-being,thus promoting patients’ rehabilitation.